Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, Cellenion Ink Comarketing Agreement for Single-Cell Proteomics

NEW YORK – Cellenion said Tuesday that it has entered a comarketing agreement with Bruker around tools for single-cell proteomics experiments.

Under the agreement, the companies will pair Lyon, France-based Cellenion's cellenOne single-cell isolation and dispensing system with Bruker's timsTOF SCP mass spectrometer to enable label-free single-cell proteomics workflows.

Cellenion's cellenOne system provides high-throughput image-based dispensing of individual cells from cell suspensions and precision dispensing of reagents to automate and miniaturize sample preparation prior to single-cell analyses, while Bruker's timsTOF SCP is specifically designed for mass spec analyses of extremely small samples, down to the single-cell level.

"We believe our expertise in precision dispensing and platform technology … and Bruker’s expertise in developing mass spectrometers such as the timsTOF SCP for single-cell proteomics are a perfect match," Holger Eickhoff, CEO of Cellenion, said in a statement.

"This partnership of unique technologies provides our users with the ability to simplify and standardize single-cell 4D-proteomics workflows," said Rohan Thakur, executive vice president of life sciences mass spectrometry at Bruker. "This is important because it allows researchers to contrast knowledge learned from decades of bulk proteomics to new discoveries being made in single-cell proteomics using the cellenOne together with the timsTOF SCP system."

Financial terms of the deal were not disclosed.

On Monday, Cellenion announced a similar comarketing agreement for single-cell proteomics with Thermo Fisher Scientific.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.